Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584708 | 0.78 | AHR (0.35) | AHR | |
| SCHEMBL21584617 | 0.76 | PTGDR2 (0.37) | PDGFRACDK5TYRO3 | |
| SCHEMBL21584605 | 0.75 | ELANE (0.41) | — | |
| SCHEMBL5847660 | 0.75 | EGFR (0.41) | — | |
| SCHEMBL22194219 | 0.74 | LMNA (0.36) | PDGFRACDK5TYRO3 | |
| Hydrochloric Acid SCHEMBL38663344 | 0.73 | EGFR (0.41) | — | |
| SCHEMBL21584830 | 0.73 | — | — | |
| SCHEMBL21584703 | 0.73 | KDM4E (0.32) | — | |
| SCHEMBL21584715 | 0.71 | GAA (0.35) | — | |
| SCHEMBL22551929 | 0.67 | PIK3CA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-111620865-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3753943-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-26 | — | — | US | disclosed |
| CN-111620865-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111620864-A | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-110156772-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技有限公司 | 2020-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | ENPP2, ATXN10, PCSK9 | PDGFRA 3763/4885CDK5 2388/4885TYRO3 4345/4885 |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ENPP2, ATXN10, PCSK9 | PDGFRA 3763/4885CDK5 2388/4885TYRO3 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.